Processing psoriasis with a specific Anti-il-23 antibody
MA46861B1Active Publication Date: 2026-08-31JANSSEN BIOTECH INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- MA46861
- Authority / Receiving Office
- MA · MA
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-11-15
- Filing Date
- 2017-11-15
- Publication Date
- 2026-08-31
- Estimated Expiration
- 2037-11-15
Abstract
The invention relates to a process for treating psoriasis in a patient previously treated by administration of an antibody against IL-12 / 23p40 and having been identified as not adequately responding thereto, by administration of an IL--23 specific antibody, for example, guselkumab, in a safe and effective amount and the patient achieves a PSI75, PASI90, PASI100 or IGA 0 or 1, measurement score, 48 weeks.
Need to check novelty before this filing date? Find Prior Art